Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

Fintel reports that on April 28, 2025, Barclays downgraded their outlook for SpringWorks Therapeutics (NasdaqGS:SWTX) from ...

Mercedes-Benz has signed a new agreement with Luminar Technologies to develop and integrate its latest lidar product, Luminar ...

After developing treatments for rare tumors, SpringWorks Therapeutics is taking a buyout offer from Germany-based Merck KGaA.

Sullivan & Cromwell is acting for longtime client Merck in its $3.9bn acquisition of US biotech company SpringWorks Therapeutics, which is being repped by Goodwin Procter.

Merck has moved to strengthen its position in oncology and rare diseases with a $3.9bn agreement to acquire SpringWorks ...

The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in SpringWorks Therapeutics (SWTX). While the effectiveness of this highly sought-after metric is ...

In a press release, Merck KGaA CEO and chair of the executive board Belen Garijo said, “The agreed acquisition of SpringWorks is a major step in our active portfolio strategy to position Merck KGaA, ...

Merck has reportedly moved to strengthen its position in oncology and rare diseases with a $3.9 billion agreement to acquire ...

The FDA and other HHS agencies of interest to the pharma sphere have seen President Donald Trump’s first 100 days as he ...

Current health news highlights include a dispute over EU drug pricing proposals, a U.S.-Mexico accord on screwworm management ...